Merck launches PhIII antiviral drug study; Celsion buoyed by interim cancer data;

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: Purdue earns a nod--and a quick slap--for abuse-resistant painkiller. News | Follow @JohnCFierce

@DamianFierce: $GILD's idelalisib will carry a boxed warning over serious liver toxicities. Here's the FDA's announcement. Release | Follow @DamianFierce

@EmilyMFierce:  GlaxoSmithKline steps closer to making world's first malaria vaccine. More from The Telegraph | Follow @EmilyMFierce

> Merck ($MRK) announced that the first patient has been enrolled in a global Phase III clinical study of letermovir (MK-8228), an investigational antiviral agent. Release

> Shares of Celsion ($CLSN) were buoyed this morning after the biotech said that it had gathered positive interim data from its ongoing open-label Phase II study of ThermoDox in recurrent chest wall breast cancer. Release

Medical Device News

@FierceMedDev: Nanoparticles point to cancerous tumors in MRIs. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Sofinnova closes $500M venture fund, keeps late-stage focus. Article | Follow @StacyALawrence

@VarunSaxena2: Frieden: "What works for Ebola is old fashioned public health." Says developing vaccine is difficult. | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: The top 5 vaccine makers brought in 86% of all vaccine sales in 2013. Find out who made the list here. Feature | Follow @EmilyWFierce

> Zimmer reports solid Q2 sales gains but lowers full-year estimates. News

> Nanoparticles point to cancerous tumors in MRIs. Story

> Augmenix aims for profitability with $10.8M Series D round as Varian acquisition option expires. More

Pharma News

@FiercePharma: Top-read in FP Weds: News flash for biopharma bosses: More than half your employees want to leave. Story | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: 3-D manufacturing being used in medical devices. When will pharma benefit? FierceMedicalDevices feature | Follow @EricPFierce

@CarlyHFierce: GlaxoSmithKline's the No. 3 vaccines maker now, but its Novartis assets may change that picture. More | Follow @CarlyHFierce

> BMJ targets Pradaxa safety, scolding Boehringer, FDA and EMA alike. Story

> Eli Lilly's Q2 profit sags on patent expirations but beats (low) expectations. Article

> Can Gilead break into cancer? With Zydelig approval, it gets its chance. More

Vaccines News

> Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo. More

> SEC charges CytoGenix CEO, 'serial con artist' with fraud. News

> Sinovac nabs Chinese vaccine tenders for hep A, influenza. Item

> GSK submits world's first malaria vaccine for EMA approval. Story

> Fluviral, FluLaval Tetra production on hold at Glaxo's troubled Quebec plant. Article

Pharma Manufacturing News

> Out with the new and in with the old after GSK trips up at vaccine plant. Story

> AmerisourceBergen deal with Walgreen reaps rewards, and costs. More

> FDA warns hospitals that Texas compounder's products are unsafe. Article

> Indian API maker voluntarily halts shipments to the U.S. Story

> Feds extract guilty plea from Turkish man accused of smuggling counterfeit Avastin. Report

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.